926 reports of this reaction
3.5% of all POSACONAZOLE reports
#6 most reported adverse reaction
PRODUCT USE IN UNAPPROVED INDICATION is the #6 most commonly reported adverse reaction for POSACONAZOLE, manufactured by Merck Sharp & Dohme LLC. There are 926 FDA adverse event reports linking POSACONAZOLE to PRODUCT USE IN UNAPPROVED INDICATION. This represents approximately 3.5% of all 26,750 adverse event reports for this drug.
Patients taking POSACONAZOLE who experience product use in unapproved indication should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PRODUCT USE IN UNAPPROVED INDICATION is moderately reported among POSACONAZOLE users, representing a notable but not dominant share of adverse events.
In addition to product use in unapproved indication, the following adverse reactions have been reported for POSACONAZOLE:
The following drugs have also been linked to product use in unapproved indication in FDA adverse event reports:
PRODUCT USE IN UNAPPROVED INDICATION has been reported as an adverse event in 926 FDA reports for POSACONAZOLE. This does not prove causation, but indicates an association observed in post-market surveillance data.
PRODUCT USE IN UNAPPROVED INDICATION accounts for approximately 3.5% of all adverse event reports for POSACONAZOLE, making it a notable side effect.
If you experience product use in unapproved indication while taking POSACONAZOLE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.